Clinical Trial Update: Open Label Extension Study of Bifeprunox [Phase 3]

View source ↗

Summary

Open-label extension of the Phase 3 trial for the antipsychotic candidate bifeprunox in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bifeprunox (bifeprunox)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED